Các xu hướng tạm thời về tỷ lệ tử vong theo nguyên nhân ở những cá nhân vừa được chẩn đoán rung nhĩ trong Nghiên cứu Tim Framingham

Jelena Kornej1, Quan Huang2, Sarah R. Preis2, Steven A. Lubitz3, Joanne M. Murabito4, Emelia J. Benjamin1, Ludovic Trinquart5
1Preventive Medicine and Section of Cardiovascular Medicine, Department of Medicine, Boston University School of Medicine, Boston, MA, USA.
2Department of Biostatistics, Boston University School of Public Health, 801 Massachusetts Avenue, Boston, MA, 02139, USA.
3Cardiovascular Research Center Massachusetts General Hospital, Boston, USA
4Section of General Internal Medicine, Department of Medicine, Boston University School of Medicine, Boston, MA, USA.
5Department of Biostatistics, Boston University School of Public Health, 801 Massachusetts Avenue, Boston, MA, 02139, USA. [email protected].

Tóm tắt

Tóm tắt Giới thiệu Tỷ lệ tử vong do tất cả nguyên nhân sau rung nhĩ (AF) đã giảm theo thời gian. Dữ liệu về các xu hướng thời gian trong các nguyên nhân tử vong ở những cá nhân mắc AF còn hạn chế. Mục tiêu của nghiên cứu của chúng tôi là phân tích các xu hướng tạm thời trong tỷ lệ tử vong theo nguyên nhân và các yếu tố dự đoán cho tử vong do bệnh tim mạch (CVD) và không do CVD ở những người tham gia có AF mới phát hiện trong Nghiên cứu Tim Framingham. Phương pháp Chúng tôi phân loại tất cả các trường hợp AF mới được chẩn đoán theo độ tuổi khi được chẩn đoán AF (<70, 70 đến <80 và ≥ 80 tuổi) và thời kỳ chẩn đoán AF (<1990, 1990–2002 và ≥ 2003). Chúng tôi theo dõi người tham gia cho đến khi qua đời hoặc lần theo dõi cuối cùng. Chúng tôi phân loại nguyên nhân tử vong thành CVD, không phải CVD, và nguyên nhân không xác định. Đối với mỗi nhóm tuổi, chúng tôi kiểm tra các xu hướng trong tỷ lệ mắc tích lũy của tử vong theo nguyên nhân qua các thời kỳ. Chúng tôi áp dụng mô hình đa biến Fine-Gray để đánh giá tỷ số rủi ro dưới phân phối (HR) giữa các yếu tố nguy cơ lâm sàng khi chẩn đoán AF và tỷ lệ tử vong theo nguyên nhân cụ thể.

Từ khóa

#rung nhĩ #tỷ lệ tử vong #bệnh tim mạch #Nghiên cứu Tim Framingham #yếu tố dự đoán #xu hướng tạm thời

Tài liệu tham khảo

Roth GA, Mensah GA, Johnson CO, Addolorato G, Ammirati E, Baddour LM, et al. Global burden of cardiovascular diseases and risk factors, 1990–2019: update from the GBD 2019 Study. J Am Coll Cardiol. 2020;76(25):2982–3021. https://doi.org/10.1016/j.jacc.2020.11.010.

Staerk L, Wang B, Preis SR, Larson MG, Lubitz SA, Ellinor PT, et al. Lifetime risk of atrial fibrillation according to optimal, borderline, or elevated levels of risk factors: cohort study based on longitudinal data from the Framingham Heart Study. BMJ. 2018;361:k1453.

Mou L, Norby FL, Chen LY, O’Neal WT, Lewis TT, Loehr LR, et al. Lifetime risk of atrial fibrillation by race and socioeconomic status: ARIC Study (Atherosclerosis Risk in Communities). Circ Arrhythm Electrophysiol. 2018;11(7):e006350. https://doi.org/10.1161/CIRCEP.118.006350.

Kornej J, Börschel C, Benjamin E, Schnabel R. Epidemiology of atrial fibrillation in the 21st century: novel methods and new insights. Circ Res. 2020;27:4–20.

Miyasaka Y, Barnes ME, Gersh BJ, Cha SS, Bailey KR, Abhayaratna WP, et al. Secular trends in incidence of atrial fibrillation in Olmsted County, Minnesota, 1980 to 2000, and implications on the projections for future prevalence. Circulation. 2006;114(2):119–25. https://doi.org/10.1161/CIRCULATIONAHA.105.595140.

Colilla S, Crow A, Petkun W, Singer DE, Simon T, Liu X. Estimates of current and future incidence and prevalence of atrial fibrillation in the U.S. adult population. Am J Cardiol. 2013;112(8):1142–7. https://doi.org/10.1016/j.amjcard.2013.05.063.

Hindricks G, Potpara T, Dagres N, Arbelo E, Bax JJ, Blomström-Lundqvist C, et al. 2020 ESC Guidelines for the diagnosis and management of atrial fibrillation developed in collaboration with the European Association of Cardio-Thoracic Surgery (EACTS). Eur Heart J. 2020.

January CT, Wann LS, Calkins H, Chen LY, Cigarroa JE, Cleveland JC Jr, et al. 2019 AHA/ACC/HRS Focused Update of the 2014 AHA/ACC/HRS Guideline for the Management of Patients with Atrial Fibrillation: a report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines and the Heart Rhythm Society in Collaboration with the Society of Thoracic Surgeons. Circulation. 2019;140(2):e125–51. https://doi.org/10.1161/CIR.0000000000000665.

Miyasaka Y, Barnes ME, Bailey KR, Cha SS, Gersh BJ, Seward JB, et al. Mortality trends in patients diagnosed with first atrial fibrillation: a 21-year community-based study. J Am Coll Cardiol. 2007;49(9):986–92. https://doi.org/10.1016/j.jacc.2006.10.062.

Schnabel RB, Yin X, Gona P, Larson MG, Beiser AS, McManus DD, et al. 50 year trends in atrial fibrillation prevalence, incidence, risk factors, and mortality in the Framingham Heart Study: a cohort study. Lancet. 2015;386(9989):154–62. https://doi.org/10.1016/S0140-6736(14)61774-8.

Freeman JV, Wang Y, Akar J, Desai N, Krumholz H. National trends in atrial fibrillation hospitalization, readmission, and mortality for Medicare beneficiaries, 1999-2013. Circulation. 2017;135(13):1227–39. https://doi.org/10.1161/CIRCULATIONAHA.116.022388.

Bassand JP, Accetta G, Camm AJ, Cools F, Fitzmaurice DA, Fox KA, et al. Two-year outcomes of patients with newly diagnosed atrial fibrillation: results from GARFIELD-AF. Eur Heart J. 2016;37(38):2882–9. https://doi.org/10.1093/eurheartj/ehw233.

Fauchier L, Villejoubert O, Clementy N, Bernard A, Pierre B, Angoulvant D, et al. Causes of death and influencing factors in patients with atrial fibrillation. Am J Med. 2016;129(12):1278–87. https://doi.org/10.1016/j.amjmed.2016.06.045.

Kuronuma K, Okumura Y, Yokoyama K, Matsumoto N, Tachibana E, Oiwa K, et al. Different determinants of vascular and nonvascular deaths in patients with atrial fibrillation: a SAKURA AF Registry substudy. J Cardiol. 2019;73(3):210–7. https://doi.org/10.1016/j.jjcc.2018.12.003.

Marijon E, Le Heuzey JY, Connolly S, Yang S, Pogue J, Brueckmann M, et al. Causes of death and influencing factors in patients with atrial fibrillation: a competing-risk analysis from the randomized evaluation of long-term anticoagulant therapy study. Circulation. 2013;128(20):2192–201. https://doi.org/10.1161/CIRCULATIONAHA.112.000491.

An Y, Ogawa H, Yamashita Y, Ishii M, Iguchi M, Masunaga N, et al. Causes of death in Japanese patients with atrial fibrillation: the Fushimi Atrial Fibrillation Registry. Eur Heart J Qual Care Clin Outcomes. 2019;5(1):35–42. https://doi.org/10.1093/ehjqcco/qcy033.

Dawber TR, Meadors GF, Moore FE Jr. Epidemiological approaches to heart disease: the Framingham Study. Am J Public Health Nations Health. 1951;41(3):279–81. https://doi.org/10.2105/AJPH.41.3.279.

Kannel WB, Dawber TR, Kagan A, Revotskie N, Stokes J 3rd. Factors of risk in the development of coronary heart disease--six year follow-up experience. The Framingham Study. Ann Intern Med. 1961;55(1):33–50. https://doi.org/10.7326/0003-4819-55-1-33.

Kannel WB, Feinleib M, McNamara PM, Garrison RJ, Castelli WP. An investigation of coronary heart disease in families. The Framingham Offspring Study. Am J Epidemiol. 1979;110(3):281–90. https://doi.org/10.1093/oxfordjournals.aje.a112813.

Lubitz SA, Yin X, Rienstra M, Schnabel RB, Walkey AJ, Magnani JW, et al. Long-term outcomes of secondary atrial fibrillation in the community: the Framingham Heart Study. Circulation. 2015;131(19):1648–55. https://doi.org/10.1161/CIRCULATIONAHA.114.014058.

Allignol A, Schumacher M, Beyersmann J. A note on variance estimation of the Aalen-Johansen estimator of the cumulative incidence function in competing risks, with a view towards left-truncated data. Biom J. 2010;52(1):126–37. https://doi.org/10.1002/bimj.200900039.

Fine JP, Gray RJ. A proportional hazards model for the subdistribution of a competing risk. J Am Stat Assoc. 1999;94(446):496–509. https://doi.org/10.1080/01621459.1999.10474144.

Geskus RB. Cause-specific cumulative incidence estimation and the fine and gray model under both left truncation and right censoring. Biometrics. 2011;67(1):39–49. https://doi.org/10.1111/j.1541-0420.2010.01420.x.

Alonso A, Krijthe BP, Aspelund T, Stepas KA, Pencina MJ, Moser CB, et al. Simple risk model predicts incidence of atrial fibrillation in a racially and geographically diverse population: the CHARGE-AF Consortium. J Am Heart Assoc. 2013;2(2):e000102. https://doi.org/10.1161/JAHA.112.000102.

Selvin E, Manzi J, Stevens LA, Van Lente F, Lacher DA, Levey AS, et al. Calibration of serum creatinine in the National Health and Nutrition Examination Surveys (NHANES) 1988-1994, 1999-2004. Am J Kidney Dis. 2007;50(6):918–26. https://doi.org/10.1053/j.ajkd.2007.08.020.

Stevens LA, Levey AS. Measured GFR as a confirmatory test for estimated GFR. J Am Soc Nephrol. 2009;20(11):2305–13. https://doi.org/10.1681/ASN.2009020171.

Conner SC, Lodi S, Lunetta KL, Casas JP, Lubitz SA, Ellinor PT, et al. Refining the association between body mass index and atrial fibrillation: G-formula and restricted mean survival times. J Am Heart Assoc. 2019;8(16):e013011. https://doi.org/10.1161/JAHA.119.013011.

Ruff CT, Giugliano RP, Braunwald E, Hoffman EB, Deenadayalu N, Ezekowitz MD, et al. Comparison of the efficacy and safety of new oral anticoagulants with warfarin in patients with atrial fibrillation: a meta-analysis of randomised trials. Lancet. 2014;383(9921):955–62. https://doi.org/10.1016/S0140-6736(13)62343-0.

Hart RG, Pearce LA, Aguilar MI. Meta-analysis: antithrombotic therapy to prevent stroke in patients who have nonvalvular atrial fibrillation. Ann Intern Med. 2007;146(12):857–67. https://doi.org/10.7326/0003-4819-146-12-200706190-00007.

Pathak RK, Middeldorp ME, Lau DH, Mehta AB, Mahajan R, Twomey D, et al. Aggressive risk factor reduction study for atrial fibrillation and implications for the outcome of ablation: the ARREST-AF Cohort Study. J Am Coll Cardiol. 2014;64(21):2222–31. https://doi.org/10.1016/j.jacc.2014.09.028.

Pathak RK, Middeldorp ME, Meredith M, Mehta AB, Mahajan R, Wong CX, et al. Long-term effect of goal-directed weight management in an atrial fibrillation cohort: a long-term follow-up study (LEGACY). J Am Coll Cardiol. 2015;65(20):2159–69. https://doi.org/10.1016/j.jacc.2015.03.002.

Yusuf S, Joseph P, Rangarajan S, Islam S, Mente A, Hystad P, et al. Modifiable risk factors, cardiovascular disease, and mortality in 155 722 individuals from 21 high-income, middle-income, and low-income countries (PURE): a prospective cohort study. Lancet. 2020;395(10226):795–808. https://doi.org/10.1016/S0140-6736(19)32008-2.

Roth GA, Forouzanfar MH, Moran AE, Barber R, Nguyen G, Feigin VL, et al. Demographic and epidemiologic drivers of global cardiovascular mortality. N Engl J Med. 2015;372(14):1333–41. https://doi.org/10.1056/NEJMoa1406656.

Collaborators GBDRF. Global burden of 87 risk factors in 204 countries and territories, 1990-2019: a systematic analysis for the Global Burden of Disease Study 2019. Lancet. 2020;396(10258):1223–49.

Hylek EM, Go AS, Chang Y, Jensvold NG, Henault LE, Selby JV, et al. Effect of intensity of oral anticoagulation on stroke severity and mortality in atrial fibrillation. N Engl J Med. 2003;349(11):1019–26. https://doi.org/10.1056/NEJMoa022913.

Collaborators GBDRF. Global, regional, and national comparative risk assessment of 79 behavioural, environmental and occupational, and metabolic risks or clusters of risks, 1990-2015: a systematic analysis for the Global Burden of Disease Study 2015. Lancet. 2016;388(10053):1659–724.

Healey JS, Oldgren J, Ezekowitz M, Zhu J, Pais P, Wang J, et al. Occurrence of death and stroke in patients in 47 countries 1 year after presenting with atrial fibrillation: a cohort study. Lancet. 2016;388(10050):1161–9. https://doi.org/10.1016/S0140-6736(16)30968-0.

Schnabel R, Pecen L, Engler D, Lucerna M, Sellal JM, Ojeda FM, et al. Atrial fibrillation patterns are associated with arrhythmia progression and clinical outcomes. Heart. 2018;104(19):1608–14. https://doi.org/10.1136/heartjnl-2017-312569.

Lubitz SA, Moser C, Sullivan L, Rienstra M, Fontes JD, Villalon ML, et al. Atrial fibrillation patterns and risks of subsequent stroke, heart failure, or death in the community. J Am Heart Assoc. 2013;2(5):e000126. https://doi.org/10.1161/JAHA.113.000126.